Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0705-0001 · 1 trial · 2 indications
Measured in number of events.
Measured in number of events.
Measured in Hour x Micromole (hr×μM).
| Arm | Type | Description |
|---|---|---|
| Part A: NNC0705-0001 | EXPERIMENTAL | Participants will receive 6 different single ascending doses of NNC0705-0001 via oral administration. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will receive single ascending dose of placebo matching NNC0705-0001 via oral administration. |
| Part B: NNC0705-0001 | EXPERIMENTAL | Participants will receive 4 different multiple ascending doses of NNC0705-0001 via oral administration. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will receive multiple ascending doses of placebo matching NNC0705-0001 via oral administration. |
| Part C: NNC0705-0001 | EXPERIMENTAL | Participants will receive 2 separate single doses of NNC0705-0001 at a previously safety-cleared dose level in PART A, either in a fed or fasted state. |
| Name | Type | Description |
|---|---|---|
| NNC0705-0001 | DRUG | NNC0705-0001 will be administered orally. |
| Placebo | DRUG | Placebo matching NNC0705-0001 will be administered orally. |
Inclusion Criteria: * Men, or women of non-childbearing potential. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 18.5 to 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. * Body weight: greater than or equal to ...
Top 20 of 28 competitors
NNC0705-0001 is an investigational small molecule medicine being developed by Novo Nordisk A/S for chronic kidney disease. It has been studied in a Phase 1 clinical trial in healthy volunteers, and it is not yet approved for any use. It belongs to the nephrology therapeutic area.
NNC0705-0001 is being developed for chronic kidney disease, a nephrology condition. The only clinical study conducted so far enrolled healthy volunteers rather than patients with chronic kidney disease, so the drug remains investigational and has no approved indication.
NNC0705-0001 is developed by Novo Nordisk A/S, the Danish pharmaceutical company whose shares trade under the ticker NVO. Novo Nordisk is the sponsor of the Phase 1 study of the compound.
NNC0705-0001 is in Phase 1 development. One Phase 1 trial has been completed, and no later-stage trials have been recorded. The compound is investigational and has not been approved by the FDA or any other regulator for chronic kidney disease or any other indication.
NNC0705-0001 has been evaluated in one completed Phase 1 trial, NCT07029568, titled a study to see how safe a new medicine (NNC0705-0001) is in healthy people. That trial enrolled 116 participants in the Netherlands, was randomized, double blind, and placebo controlled, and included healthy volunteers and people with chronic kidney disease.